Ally Olotu

In the News

Study establishes link between gender, extramarital affairs and HIV

Dar es Salaam. A new Ifakara Health Institute study has found “a significant association between lifetime (proxy) extramarital affairs and HIV infection among women only,” with the risk being significantly …

IHI names winners of research, innovation fund

[Right-Left] Getrud, Beatrice, Theckla, and Tutu.Ifakara Health Institute (IHI) has named recipients of the 2017/18 Director’s Research and Innovation Fund. This is an internal funding mechanism aimed to support specific …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

Ally Olotu

Research Scientist & Clinician

Dr Ally Olotu is research physician with expertise in malaria epidemiology and clinical trials addressing malaria interventions such as malaria vaccines. After 2 years of clinical practice at Aga Khan Hospital in Dar es salaam, Tanzania he worked as a research clinician within several clinical studies of malaria pathogenesis at KEMRI-Wellcome Trust, Kenya. In 2005, he was awarded a WHO/TDR Career Development Fellowship in malaria vaccine development and spent a year at GSK Biologicals in Rixensart, Belgium and WHO/TDR headquarters in Geneva, Switzerland where he received training in training in malaria vaccine research and development and clinical trials management. He was also involved in coordinating two malaria vaccine trials in West Africa and played a role in the development of clinical trial protocols and standard operating procedures. He was a Co-PI in a multi-centre trial evaluating the safety and efficacy of RTS,S/AS01, a candidate malaria vaccine, and participated in setting up a clinical trial facility which provided support to the trial.  After the end of the industry-sponsored study, and under the supervision of Dr Philip Bejon, He initiated an investigator-led extension which formed the basis of his DPhil work which started in 2010 and ended in 2014. In 2015, He joined the Ifakara Health Institute where he was assigned to supervise the Equatorial Guinea Malaria Vaccine Initiative research project in Malabo, Bioko Island. Over the last 2 years, and working with both the public and private partners, he participated in the development of the protocols and SOPs for a whole sporozoite vaccine trial and trained a clinical trial team which successfully implemented the first ever clinical trial in the history of Equatorial Guinea.  His main contribution has been on the investigation of the long-term efficacy of a candidate malaria vaccine (RTS,S/AS01) in young children living in a malaria endemic country. He has also described the interaction between the vaccine efficacy and malaria exposure. In addition he has studied immunological markers of vaccine efficacy and of naturally-acquired infection. His research to-date has led to several publication in peer reviewed journals. In 2013 he won the Oxford University Nuffield Department of Medicine Graduate Research Prize for his DPhil work. He is currently collaborating with Sanaria Inc, Medical Care Development International in Equatorial Guinea and Swiss Tropical Public Health Institute

View Dr. Olotu’s Research Interests and Publications


Evaluation of whole sporozoite vaccines for malaria elimination

© Ifakara Health Institute (IHI), 2016